. 2021 Sep 27;13(9):1154–1166. doi: 10.4254/wjh.v13.i9.1154
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Figure 3.
Suggested mechanism of action of probiotics in metabolic associated fatty liver disease.